Pharma BD Deal Intelligence

Webster Equity Partners / Lifecore Biomedical, Inc.

2026 · Take-Private · $664M · Pending

Lifecore Biomedical (Nasdaq: LFCR), a sterile injectable contract development and manufacturing organisation, agreed to be acquired and taken private by an entity affiliated with Webster Equity Partners. Holders receive USD 6.28 in cash per share at closing, a premium of approximately 49.5 percent to the 25 September 2026 close, plus one non-tradable contingent value right per share. The CVRs provide up to USD 160 million in additional aggregate payments tied to revenue milestones for 2028 (USD 30 million) and 2029 (USD 45 million) and an EBITDA milestone for 2030 (USD 85 million). Full milestone achievement would bring aggregate consideration to up to USD 9.67 per share, approximately a 130.2 percent premium, and total transaction value to up to USD 663.7 million. Closing is expected at the end of the fourth quarter of 2026, subject to stockholder and regulatory approvals.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals